Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase 2a EBA Trial of AZD5847

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT01516203
First received: January 19, 2012
Last updated: April 16, 2014
Last verified: April 2014
  Purpose

The purpose of this study is to assess the early bacterial activity (EBA) from day 0 to day 14 of Astra Zeneca Drug (AZD5847) at four different doses and schedules (500 mg once daily, 500 mg twice daily, 1200 mg once daily, and 800 mg twice daily) in subjects with newly-diagnosed sputum smear positive pulmonary TB. A total of 75 subjects will be enrolled, with 15 randomized to each AZD5847 study arm or standard treatment with Rifafour. Duration of drug treatment is 14 days.


Condition Intervention Phase
Tuberculosis
Drug: Rifafour
Drug: AZD5847
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized, Open Label, Multiple Dose Phase 2a Study of the Early Bactericidal Activity of AZD5847 in Adults With Pulmonary Tuberculosis

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • Early Bactericidal Activity: Rate of change in sputum colony forming unit (CFU) counts (bactericidal activity) during the entire 14 days of study drug administration (EBA0-14) [ Time Frame: Day 0 to Day 14 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in urine, sputum, and serum metabolomic biomarkers over the periods (baseline and Days 8, 14) [ Time Frame: Baseline and Days 8, 14 ] [ Designated as safety issue: No ]
  • The change in time after inoculation until culture detection (time to detection; TTD) in MGIT enriched liquid culture media over the period Day 2 to Day 14 [ Time Frame: Day 2 to Day 14 ] [ Designated as safety issue: No ]
  • The change in time after inoculation until culture detection (time to detection; TTD) in MGIT enriched liquid culture media over the period Day 0 to Day 2 [ Time Frame: Day 0 to Day 2 ] [ Designated as safety issue: No ]
  • Rate of change in sputum CFU counts (bactericidal activity) during the first 2 days of study drug administration (traditional EBA; EBA0-2) [ Time Frame: Day 0 to Day 2 ] [ Designated as safety issue: No ]
  • The change in time after inoculation until culture detection (time to detection; TTD) in Mycobacterial Growth Indicator Tube (MGIT) enriched liquid culture media over the period Day 0 to Day 14 [ Time Frame: Day 0 to Day 14 ] [ Designated as safety issue: No ]
  • Change in Mycobacterium tuberculosis (MTB) mRNA in sputum by RT-PCR for fbpB, hspX, icl1, rrnA-p1 and other specific mycobacterial mRNA targets of interest over the periods (baseline and Days 2, 4, 8, 14) [ Time Frame: Baseline and Days 2, 4, 8, 14 ] [ Designated as safety issue: No ]
  • Pharmacokinetic and pharmacodynamic parameters Tmax, Cmax, half life, AUC, AUC/MIC, Cmax, Cmax/MIC, time > MIC using non-compartmental analysis, compartmental and population models [ Time Frame: Day 1, 3, 5, 10 and 14 ] [ Designated as safety issue: No ]
  • Rate of change in sputum CFU counts (bactericidal activity) during the first 2 to 14 days of study drug administration (traditional EBA; EBA2-14) [ Time Frame: Day 2 to Day 14 ] [ Designated as safety issue: No ]
  • Adverse event collection: Complete blood count, coagulation panels, liver function tests, Creatine phosphokinase, urinalysis and 12-lead electrocardiograms as well as unsolicited events (adverse events, serious adverse events). [ Time Frame: Day 0 to Day 28 ] [ Designated as safety issue: Yes ]

Enrollment: 75
Study Start Date: December 2012
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 2
AZD5847 500 mg orally twice daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
Drug: AZD5847
Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.
Experimental: Arm 3
AZD5847 1200 mg orally once daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
Drug: AZD5847
Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.
Experimental: Arm 4
AZD5847 800 mg orally twice daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
Drug: AZD5847
Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.
Experimental: Arm 1
AZD5847 500 mg orally once daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
Drug: AZD5847
Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.
Active Comparator: Arm 5
Rifafour e-275 mg tablets given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
Drug: Rifafour
Eligible subjects will be randomly assigned to receive treatment with standard 4 drug anti-tuberculosis regimen: Rifafour e-275 mg tablets (75 mg isoniazid/150 mg Rifampin/275 mg Ethambutol/400 mg Pyrazinamide) orally, dosed by body weight for 14 days.

Detailed Description:

This is a study of early bactericidal activity (EBA) in treatment-naïve patients with active pulmonary tuberculosis. This prospective, randomized, open-label study that will compare the effect of monotherapy with each of four dose levels of AZD5847 to that of an active control (Rifafour administered orally once daily) on the concentration of Mycobacterium tuberculosis (M. tb) in expectorated sputum (colony-forming units per mL of sputum). Daily quantitative sputum cultures will be performed during treatment and analyzed by investigators who will be blinded to the assigned treatment. The duration of therapy will be 14 days in order to support an assessment of early bactericidal activity (days 0-2) and sterilizing activity (days 3-14). Because of the risk of emergence of drug resistance in TB patients treated with a single active drug, regulatory and ethical requirements restrict monotherapy to a maximum duration of 14 days (EMEA Draft TB Guidance 2008). The study will utilize a standard design and will thus support comparison with other marketed and investigational antimycobacterial agents (Donald and Diacon 2008). The primary aim of the study is to assess the EBA 0-14 of AZD5847 at four different doses and schedules (500 mg once daily, 500 mg twice daily, 1200 mg once daily, and 800 mg twice daily) in subjects with newly-diagnosed sputum smear positive pulmonary TB. The secondary aim is to assess the EBA 0-2 and EBA 2-14 of AZD5847 at the above doses.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults, male or female, age 18 to 65 years
  • Post-menopausal women under the age of 65 years will be included in the study. Women of childbearing potential must be using or agree to use an adequate method of birth control through the end of study follow up. These methods include: total sexual abstinence; a single male partner who has been vasectomized combined with use of a condom; a combination of two effective birth control methods from the following list:

    1. an intrauterine device plus a condom;
    2. a tubal ligation (tubes tied) plus a condom;
    3. Depo-provera injections plus a condom;
    4. Intravaginal ring plus a condom
  • Newly diagnosed sputum smear-positive pulmonary tuberculosis as confirmed by at least one sputum AFB + smear (at least grade 1+ using the WHO/IUATLD grading scale)
  • Willing and able to provide informed consent
  • Hemoglobin >/= 8 gm/dL
  • Serum creatinine < 2 mg/dL (<176.8 umol/L)
  • Serum AST < 3.0 times the upper limit of normal for the testing laboratory and total bilirubin < 1.3 mg/dL
  • Random blood glucose < 150 mg/dL (< 8.32 mmol/L)
  • If HIV-positive, not currently on ART, CD4 count> 350 muL^-1 and/or no need to start ART in the opinion of the local investigator
  • Cough productive of at least 10 ml (two teaspoons) of sputum daily per patient report over the week prior to enrollment.
  • Chest radiograph compatible with pulmonary TB.
  • Negative sputum Xpert™ MTB/RIF test for rifampin resistance.
  • Negative urine pregnancy test

Exclusion Criteria:

  • HIV infection with CD4 count of </=350muL^-1 and/or the need to start ART in the opinion of the local investigator.
  • Weight less than 40 kg or greater than 90 kg
  • Presence of hemoptysis. Subjects who cough up frank blood (more than blood streaked sputum) will not be eligible for enrollment.
  • Subjects with rifampin resistance as determined by the Xpert test as screening.
  • Pregnant or breastfeeding women
  • Presence of pneumothorax on pretreatment chest radiograph
  • Clinical suspicion of disseminated tuberculosis or tuberculous meningitis or pulmonary TB requiring immediate start of standard chemotherapy in the opinion of the local investigator
  • Presence of serious underlying medical illness, such as liver failure, renal failure,any diabetes mellitus, chronic alcoholism (> 3 alcoholic drinks per day), decompensated heart failure, cardiac arrhythmias, hematologic malignancy or subjects receiving myelosuppressive chemotherapy.
  • Allergy or contraindication to study drugs
  • Prior treatment for TB with antituberculous medications (isoniazid, rifampin, pyrazinamide, ethambutol or streptomycin or those treated with other antibiotics with known activity against MTB during the preceding 6 months (for example aminoglycosides, fluoroquinolones, carbapenems and linezolid)
  • Subjects taking monoamine oxidase (MAO) inhibitors or selective serotonin release inhibitor (SSRI) medications
  • Total white blood cell count less than 3000/mm^3
  • Platelet count less than 150,000/mm^3
  • Subjects with QTcF> 450 msec, QTcF < 340 msec, and/or family history of long QT syndrome
  • Subjects unlikely in the opinion of the local investigator to be able to comply with the requirements of the study protocol
  • Subjects whose urine tests positive for INH metabolites, indicating they are already receiving anti-TB treatment.
  • History of tuberculosis less than 5 years ago, history of more than one episode of tuberculosis, history of drug resistant tuberculosis, or household contact with an individual who has confirmed drug-resistant tuberculosis.
  • Known arrhythmias or other cardiac conditions
  • Active severe dermatologic disease (Grade 3 or Grade 4 per DMID Adult Toxicity Table)
  • Immunosuppressive conditions or receiving immunosuppressive medications
  • A history of optic neuritis.
  • Subjects on antiretroviral therapy for HIV (including AZT, 3TC, FTC, D4T, ddI, ddC, tenofovir, abacavir, nevirapine, efavirenz, ritonavir, lopinavir, atazanavir, saquinavir, darunavir, indinavir, raltegravir)
  • Subjects taking drugs capable of prolonging the QTc interval, such as type Ia and III anti-arrhythmics
  • Random urine toxicology screen positive for cocaine or methamphetamines.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01516203

Locations
South Africa
Task Clinical Research Centre
Ekurhuleni, Gauteng, South Africa, 7530
Sponsors and Collaborators
  More Information

No publications provided

Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT01516203     History of Changes
Other Study ID Numbers: 11-0006, N01AI70022C
Study First Received: January 19, 2012
Last Updated: April 16, 2014
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board
United States: Federal Government
South Africa: Medicines Control Council

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Mycobacterium tuberculosis, AZD5847, Rifafour, dose-ranging, tuberculosis

Additional relevant MeSH terms:
Tuberculosis
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Mycobacterium Infections

ClinicalTrials.gov processed this record on November 25, 2014